TY - JOUR
T1 - Awareness of hepatitis C infection among women with and at risk for HIV
AU - Cohen, Mardge H.
AU - Grey, Dennis
AU - Cook, Judith A.
AU - Anastos, Kathryn
AU - Seaberg, Eric
AU - Augenbraun, Michael
AU - Burian, Pam
AU - Peters, Marion
AU - Young, Mary
AU - French, Audrey
N1 - Funding Information:
Acknowledgment: The WIHS is funded by the National Institute of Allergy and Infectious Diseases, with supplemental funding from the National Cancer Institute, the National Institute of Child Health & Human Development, the National Institute on Drug Abuse, the Agency for Health Care Policy and Research, and the National Center for Research Resources. Grant numbers U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-HD-32632, U01-AI-34993, U01-AI-42590, MO1-RRR00071, MO1-RR00079, and MO1-RR00083.
PY - 2007/12
Y1 - 2007/12
N2 - BACKGROUND: Treatment guidelines recommend all HIV/HCV-co-infected persons be considered for hepatitis C virus (HCV) treatment, yet obstacles to testing and accessing treatment for HCV continue for women. OBJECTIVE: To assess awareness of HCV, and describe diagnostic referrals and HCV treatment among women in the Women's Interagency HIV Study (WIHS). DESIGN: Prospective epidemiologic cohort. PARTICIPANTS: Of 3,768 HIV-infected and uninfected women in WIHS, 1,166 (31%) were HCV antibody positive. MEASUREMENTS AND MAIN RESULTS: Awareness of HCV infection and probability of referrals for diagnostic evaluations and treatment using logistic regression. Follow-up HCV information was available for 681 (390 died, 15 withdrew, 80 missed visit) in 2004. Of these 681, 522 (76.7%) reported knowing their HCV diagnosis. Of these, 247 of 522 (47.3%) stated their providers recommended a liver biopsy, whereas 139 of 247 or 56.3% reported having a liver biopsy. A total of 170 of 522 (32.6%) reported being offered treatment and 74.1% (n=126 of 170) reported receiving HCV treatment. In multivariate regression analyses, African-American race, Hispanic/Latina ethnicity, poverty, and current crack/cocaine/heroin use were negatively associated with treatment referrals, whereas elevated alanine aminotransferase (ALT) was associated with increased likelihood of referral and increased likelihood of treatment. CONCLUSION: One quarter of women with HCV in this cohort were not aware of their diagnosis. Among those aware of their HCV, 1 in 4 received liver biopsy and treatment for HCV. Both provider and patient education interventions regarding HCV testing and HCV treatment options and guidelines are needed to enhance HCV awareness and participation in HCV evaluation and treatment.
AB - BACKGROUND: Treatment guidelines recommend all HIV/HCV-co-infected persons be considered for hepatitis C virus (HCV) treatment, yet obstacles to testing and accessing treatment for HCV continue for women. OBJECTIVE: To assess awareness of HCV, and describe diagnostic referrals and HCV treatment among women in the Women's Interagency HIV Study (WIHS). DESIGN: Prospective epidemiologic cohort. PARTICIPANTS: Of 3,768 HIV-infected and uninfected women in WIHS, 1,166 (31%) were HCV antibody positive. MEASUREMENTS AND MAIN RESULTS: Awareness of HCV infection and probability of referrals for diagnostic evaluations and treatment using logistic regression. Follow-up HCV information was available for 681 (390 died, 15 withdrew, 80 missed visit) in 2004. Of these 681, 522 (76.7%) reported knowing their HCV diagnosis. Of these, 247 of 522 (47.3%) stated their providers recommended a liver biopsy, whereas 139 of 247 or 56.3% reported having a liver biopsy. A total of 170 of 522 (32.6%) reported being offered treatment and 74.1% (n=126 of 170) reported receiving HCV treatment. In multivariate regression analyses, African-American race, Hispanic/Latina ethnicity, poverty, and current crack/cocaine/heroin use were negatively associated with treatment referrals, whereas elevated alanine aminotransferase (ALT) was associated with increased likelihood of referral and increased likelihood of treatment. CONCLUSION: One quarter of women with HCV in this cohort were not aware of their diagnosis. Among those aware of their HCV, 1 in 4 received liver biopsy and treatment for HCV. Both provider and patient education interventions regarding HCV testing and HCV treatment options and guidelines are needed to enhance HCV awareness and participation in HCV evaluation and treatment.
KW - Drug use
KW - HIV
KW - Hepatitis C
KW - Race
KW - Therapy
KW - Women
UR - http://www.scopus.com/inward/record.url?scp=36349018813&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36349018813&partnerID=8YFLogxK
U2 - 10.1007/s11606-007-0395-x
DO - 10.1007/s11606-007-0395-x
M3 - Article
C2 - 17924170
AN - SCOPUS:36349018813
SN - 0884-8734
VL - 22
SP - 1689
EP - 1694
JO - Journal of general internal medicine
JF - Journal of general internal medicine
IS - 12
ER -